News & Events about Vaxcyte Inc.
-- Breakthrough Therapy Designation for 24-Valent Investigational Pneumococcal Conjugate Vaccine Candidate Based on Positive Topline Proof-of-Concept Data Results in Adults Aged 18-64 That Suggest Potential Best-in-Class Profile -- -- Topline Safety, Tolerability and Immunogenicity Data from VAX-24 ...
Globe Newswire
3 months ago
SAN CARLOS, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of ...
Thinking about buying stock in Vaxcyte, Frontline, Avis Budget Group, ServiceNow, or Wolfspeed? Thinking about buying stock in Vaxcyte, Frontline, Avis Budget Group, ServiceNow, or Wolfspeed? PR Newswire NEW YORK, Oct. 24, 2022 NEW YORK, Oct. 24, 2022 /PRNewswire/ -- InvestorsObserverissues...
Vaxcyte, Inc. (NASDAQ:PCVX Get Rating) COO Jim Wassil sold 2,800 shares of Vaxcyte stock in a transaction that occurred on Monday, October 17th. The stock was sold at an average price of $25.72, for a total transaction of $72,016.00. Following the sale, the chief operating officer now owns 42,344 ...